Risk factors for brain relapse in patients with metastatic breast cancer

被引:125
作者
Slimane, K
Andre, F
Delaloge, S
Dunant, A
Perez, A
Grenier, J
Massard, C
Spielmann, M
机构
[1] Inst Gustave Roussy, Breast Canc Unit, Dept Med, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Biostat, F-94805 Villejuif, France
关键词
brain metastases; breast cancer; chemotherapy; hormone receptor; lung metastases; radiotherapy;
D O I
10.1093/annonc/mdh432
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The occurrence of brain metastases is an emerging problem in patients with metastatic breast cancer. In the present study, we looked at risk factors for brain metastasis among patients with metastatic breast cancer. Patients and methods: The risk factors for brain metastasis were first determined in a series of 215 patients with metastatic breast cancer. Risk factors identified in the multivariate analysis were re-evaluated in a confirmatory series of 199 patients with metastatic breast cancer. All the patients had been included in prospective randomized trials that evaluated chemotherapy or endocrine therapy in an adjuvant setting. Results: In the first series, the presence of lung metastases (hazard ratio =4.3, 95% CI: 1.9-9.3, P=0.0003) and negative hormone receptor status (hazard ratio=4.2, 95% CI: 1.7-11, P=0.002) were the only predictive factors associated with the occurrence of brain metastases in the multivariate analysis. The second series confirmed that the presence of lung metastases and negative hormone receptor status were associated with the occurrence of brain metastases. Conclusion: The presence of lung metastases as the first site of relapse and a negative hormone receptor status are predictive for the occurrence of brain metastases in patients with metastatic breast cancer. A prophylactic treatment should be evaluated in these subsets of patients.
引用
收藏
页码:1640 / 1644
页数:5
相关论文
共 23 条
  • [1] High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel
    Abali, H
    Çelik, I
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 632 - 633
  • [2] Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen
    Arriagada, R
    Spielmann, M
    Koscielny, S
    Le Chevalier, T
    Delozier, T
    Ducourtieux, M
    Tursz, T
    Hill, C
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (09) : 1378 - 1386
  • [3] ARRIAGADA R, 2003, P AN M AM SOC CLIN, V22, pA14
  • [4] Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
    Aupérin, A
    Arriagada, R
    Pignon, JP
    Le Péchoux, C
    Gregor, A
    Stephens, RJ
    Kristjansen, PEG
    Johnson, BE
    Ueoka, H
    Wagner, H
    Aisner, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) : 476 - 484
  • [5] Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    Bendell, JC
    Domchek, SM
    Burstein, HJ
    Harris, L
    Younger, J
    Kuter, I
    Bunnell, C
    Rue, M
    Gelman, R
    Winer, E
    [J]. CANCER, 2003, 97 (12) : 2972 - 2977
  • [6] Survival of patients with metastatic breast carcinoma - Importance of prognostic markers of the primary tumor
    Chang, J
    Clark, GM
    Allred, DC
    Mohsin, S
    Chamness, G
    Elledge, RM
    [J]. CANCER, 2003, 97 (03) : 545 - 553
  • [7] CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL collaborative group overview of 43 randomized trials
    Clarke, M
    Gaynon, P
    Hann, I
    Harrison, G
    Masera, G
    Peto, R
    Richards, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1798 - 1809
  • [8] Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:: antitumor activity and correlation with vascular endothelial growth factor levels
    Colleoni, M
    Rocca, A
    Sandri, MT
    Zorzino, L
    Masci, G
    Nolè, F
    Peruzzotti, G
    Robertson, C
    Orlando, L
    Cinieri, S
    de Braud, F
    Viale, G
    Goldhirsch, A
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (01) : 73 - 80
  • [9] High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
    Crivellari, D
    Pagani, O
    Veronesi, A
    Lombardi, D
    Nolè, F
    Thürlimann, B
    Hess, D
    Borner, M
    Bauer, J
    Martinelli, G
    Graffeo, R
    Sessa, C
    Goldhirsch, A
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (03) : 353 - 356
  • [10] Determinants and prognoses of locoregional and distant progression in breast cancer
    Engel, J
    Eckel, R
    Aydemir, Ü
    Aydemir, S
    Kerr, J
    Schlesinger-Raab, A
    Dirschedl, P
    Hölzel, D
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (05): : 1186 - 1195